Sun, Xin

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Xie, L., Xu, J., Sun, X., Guo, W., Gu, J., Liu, K., Zheng, B., Ren, T., Huang, Y., Tang, X., et al. (2020) · Journal for ImmunoTherapy of Cancer

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 145

Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial

Xie, L., Xu, J., Sun, X., Tang, X., Yan, T., Yang, R., & Guo, W. (2019) · The Oncologist

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 128

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres

Xie, L., Xu, J., Sun, X., Li, X., Liu, K., Liang, X., Zhou, Z., Zhuang, H., Sun, K., Wu, Y., et al. (2021) · Oncology Letters

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 19

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

Xie, L., Liang, X., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Tang, X., Li, X., Zhan, X., et al. (2023) · BMC Cancer

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 14

Leveraging artificial intelligence for predicting spontaneous closure of perimembranous ventricular septal defect in children: a multicentre, retrospective study in China

Sun, J., Feng, T., Wang, B., Li, F., Han, B., Chu, M., Gong, F., Yi, Q., Zhou, X., Chen, S., et al. (2025) · The Lancet Digital Health

Congenital Heart Disease StudiesCardiovascular and Diving-Related Complications

Cited by 9